ZA97283B - Isolated tyrosinase derived peptides and uses thereof - Google Patents
Isolated tyrosinase derived peptides and uses thereofInfo
- Publication number
- ZA97283B ZA97283B ZA97283A ZA97283A ZA97283B ZA 97283 B ZA97283 B ZA 97283B ZA 97283 A ZA97283 A ZA 97283A ZA 97283 A ZA97283 A ZA 97283A ZA 97283 B ZA97283 B ZA 97283B
- Authority
- ZA
- South Africa
- Prior art keywords
- derived peptides
- tyrosinase derived
- isolated
- isolated tyrosinase
- peptides
- Prior art date
Links
- 102000003425 Tyrosinase Human genes 0.000 title 1
- 108060008724 Tyrosinase Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
- C12Y114/18001—Tyrosinase (1.14.18.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Virology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/587,391 US5744316A (en) | 1992-12-22 | 1996-01-17 | Isolated, tyrosinase derived peptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA97283B true ZA97283B (en) | 1997-07-30 |
Family
ID=24349607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA97283A ZA97283B (en) | 1996-01-17 | 1997-01-14 | Isolated tyrosinase derived peptides and uses thereof |
Country Status (8)
Country | Link |
---|---|
US (1) | US5744316A (fr) |
JP (1) | JP2000505417A (fr) |
CN (1) | CN1209876A (fr) |
AU (1) | AU711445B2 (fr) |
CA (1) | CA2242376A1 (fr) |
NZ (1) | NZ330991A (fr) |
WO (1) | WO1997026535A1 (fr) |
ZA (1) | ZA97283B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
CA2318979A1 (fr) * | 1998-01-26 | 1999-07-29 | Genzyme Corporation | Cellules specifiques d'antigenes, procedes de production et utilisations associes |
US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
US6667037B1 (en) | 1998-10-09 | 2003-12-23 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof |
JP4540033B2 (ja) | 1999-10-22 | 2010-09-08 | サノフィ パストゥール リミテッド | 腫瘍抗原に対する免疫応答を誘発および/または増強する方法 |
US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
EP2278023A1 (fr) * | 2000-04-28 | 2011-01-26 | Mannkind Corporation | Peptide multiepitope de Melan-A/MART-1 et leur utilisation dans des procédés d'immunsation anti-tumorale |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
WO2003008537A2 (fr) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Sequences d'epitope |
EP1752160A3 (fr) * | 2001-04-06 | 2007-05-30 | Mannkind Corporation | Sequences d'epitopes |
US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
EP2314712B1 (fr) * | 2001-11-07 | 2014-01-08 | Mannkind Corporation | Vecteurs d´expression codant pour des épitopes d´antigènes et procédés permittant leur conception |
US20060165711A1 (en) * | 2004-12-29 | 2006-07-27 | Bot Adrian I | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
EP2351576A1 (fr) * | 2004-12-29 | 2011-08-03 | Mannkind Corporation | Procédés pour déclencher, maintenir et manipuler les réponses immunologiques par l'administration ciblée de modificateurs de réponse biologique dans des organes lymphoïdes |
CN101384261B (zh) * | 2005-12-22 | 2011-12-07 | 海德拉生物科学公司 | 治疗疼痛的组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4898814A (en) * | 1986-10-06 | 1990-02-06 | Donald Guthrie Foundation For Medical Research, Inc. | A cDNA clone for human tyrosinase |
US5487391A (en) * | 1994-01-28 | 1996-01-30 | Ep Technologies, Inc. | Systems and methods for deriving and displaying the propagation velocities of electrical events in the heart |
-
1996
- 1996-01-17 US US08/587,391 patent/US5744316A/en not_active Expired - Lifetime
-
1997
- 1997-01-14 JP JP9526244A patent/JP2000505417A/ja active Pending
- 1997-01-14 NZ NZ330991A patent/NZ330991A/en unknown
- 1997-01-14 ZA ZA97283A patent/ZA97283B/xx unknown
- 1997-01-14 CN CN97191765A patent/CN1209876A/zh active Pending
- 1997-01-14 WO PCT/US1997/000834 patent/WO1997026535A1/fr active Application Filing
- 1997-01-14 CA CA002242376A patent/CA2242376A1/fr not_active Abandoned
- 1997-01-14 AU AU17508/97A patent/AU711445B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU1750897A (en) | 1997-08-11 |
WO1997026535A1 (fr) | 1997-07-24 |
AU711445B2 (en) | 1999-10-14 |
NZ330991A (en) | 1999-10-28 |
CA2242376A1 (fr) | 1997-07-24 |
JP2000505417A (ja) | 2000-05-09 |
CN1209876A (zh) | 1999-03-03 |
US5744316A (en) | 1998-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL128529A0 (en) | Anti-inflammatory peptides and uses thereof | |
EP1064022A4 (fr) | Peptides de liaison de hla et leurs applications | |
EP0894807A4 (fr) | COMPLEXE GPIb-LIPIDE ET SES UTILISATIONS | |
AU6241698A (en) | Tace-like and matrilysin-like polypeptides | |
EP0888120A4 (fr) | Peptides de liaison aux hla et utilisations | |
PL346346A1 (en) | Cyclic prosaposin-derived peptides and uses thereof | |
ZA97283B (en) | Isolated tyrosinase derived peptides and uses thereof | |
GB9608130D0 (en) | Adam proteins and uses thereof | |
HUP9700446A3 (en) | Oilsuspension-concentrate and using thereof | |
GB9806806D0 (en) | Peptides and uses thereof | |
ZA9711156B (en) | HVEM polypeptides and uses thereof | |
EP0750679A4 (fr) | Peptides isoles derives de la tyrosinase et leurs utilisations | |
EP1015474A4 (fr) | Gene don-1, polypeptides et utilisations de ceux-ci | |
IL128556A0 (en) | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | |
ZA964825B (en) | Collagen peptide fraction and its uses. | |
GB9718110D0 (en) | Peptides | |
EP0901502A4 (fr) | Peptides lytiques | |
GB9714276D0 (en) | Peptides and related compounds | |
GB9700154D0 (en) | Peptides | |
PL328334A1 (en) | Preparation and application thereof | |
EP0996457A4 (fr) | Peptides liberateurs de f.s.h. | |
AU4986097A (en) | Thrombin receptor peptides and uses thereof | |
GB9606272D0 (en) | Gene and peptides | |
ZA951610B (en) | Isolated tyrosinase derived peptides and uses thereof | |
GB9613705D0 (en) | Novel peptides |